Limits...
Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE).

Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C - Med. Sci. Monit. (2011)

Bottom Line: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications.After DEB-TACE mean survival was significantly prolonged with 651 ± 76 days vs. 414 ± 43 days for cTACE (p=0.01).Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Dresden University of Technology, Dresden, Germany. openphw@googlemail.com

ABSTRACT

Background: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis.

Material/methods: A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean survival was performed. Tumour response was evaluated in accordance with the European Association for the Study of the Liver (EASL) response criteria by two radiologists in consensus reading.

Results: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications. Objective Response (OR, complete response + partial response) for DEB-TACE was 22.7%; a further 68.2% was stable disease (SD). The respective response rates for the cTACE were OR 22.7 and SD 31.8%. Thus disease control was not significantly increased for DEB TACE (p=0.066). After DEB-TACE mean survival was significantly prolonged with 651 ± 76 days vs. 414 ± 43 days for cTACE (p=0.01).

Conclusions: Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.

Show MeSH

Related in: MedlinePlus

Survival: Kaplan-Meier curves for all patients in both groups, censored data come from patients who were still alive at the end of the study.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3539521&req=5

f7-medscimonit-17-4-cr189: Survival: Kaplan-Meier curves for all patients in both groups, censored data come from patients who were still alive at the end of the study.

Mentions: The survival in the cTACE group was 414±43 days on average (95% CI; 329–499) and 651±76 days (95% CI; 502–800) in the DEB-TACE group. The influence of the form of therapy on the survival rate was significant in the log-rank test (p=0.01). The corresponding one-year survival probability was 55% in the cTACE group and 70% in the DEB-TACE group (Figure 7).


Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE).

Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C - Med. Sci. Monit. (2011)

Survival: Kaplan-Meier curves for all patients in both groups, censored data come from patients who were still alive at the end of the study.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3539521&req=5

f7-medscimonit-17-4-cr189: Survival: Kaplan-Meier curves for all patients in both groups, censored data come from patients who were still alive at the end of the study.
Mentions: The survival in the cTACE group was 414±43 days on average (95% CI; 329–499) and 651±76 days (95% CI; 502–800) in the DEB-TACE group. The influence of the form of therapy on the survival rate was significant in the log-rank test (p=0.01). The corresponding one-year survival probability was 55% in the cTACE group and 70% in the DEB-TACE group (Figure 7).

Bottom Line: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications.After DEB-TACE mean survival was significantly prolonged with 651 ± 76 days vs. 414 ± 43 days for cTACE (p=0.01).Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Dresden University of Technology, Dresden, Germany. openphw@googlemail.com

ABSTRACT

Background: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis.

Material/methods: A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean survival was performed. Tumour response was evaluated in accordance with the European Association for the Study of the Liver (EASL) response criteria by two radiologists in consensus reading.

Results: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications. Objective Response (OR, complete response + partial response) for DEB-TACE was 22.7%; a further 68.2% was stable disease (SD). The respective response rates for the cTACE were OR 22.7 and SD 31.8%. Thus disease control was not significantly increased for DEB TACE (p=0.066). After DEB-TACE mean survival was significantly prolonged with 651 ± 76 days vs. 414 ± 43 days for cTACE (p=0.01).

Conclusions: Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.

Show MeSH
Related in: MedlinePlus